Oryzon Genomics SA
MAD:ORY
Oryzon Genomics SA
MAD:ORY
Price:
3.12
EUR
-0.79%
Market Closed
Market Cap:
€249.3m
Relative Value
The Relative Value of one
ORY
stock under the Base Case scenario is
0.32
EUR.
Compared to the current market price of 3.12 EUR,
Oryzon Genomics SA
is
Overvalued by 90%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ORY
Relative Value
Base Case
0.32
EUR
Overvaluation 90%
Multiples Across Competitors
ORY Competitors Multiples
Oryzon Genomics SA Competitors
Oryzon Genomics SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ES |
|
Oryzon Genomics SA
MAD:ORY
|
241.8m EUR | 0 | -91.2 | -43.9 | -42.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
399.2B USD | 6.7 | 170 | 16.5 | 23.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD | 5.5 | 26.2 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.1B USD | 6.4 | 22.1 | 15 | 15 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121B USD | 10.1 | 30.6 | 23.4 | 24.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD | 5.7 | 18.3 | 13.8 | 15.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
74.2B AUD | 3.3 | 17.2 | 11.7 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR | 14.2 | 33.5 | 57.5 | 59.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
